Envarsus XR is a prescription medication used to prevent organ rejection in adult patients receiving a kidney transplant [1]. It is an extended-release formulation of tacrolimus [1].
What is the active ingredient in Envarsus XR?
The active ingredient in Envarsus XR is tacrolimus [1]. Tacrolimus is a calcineurin inhibitor, a type of immunosuppressant medication that works by decreasing the activity of the immune system [1].
How does Envarsus XR work?
Envarsus XR helps prevent the body's immune system from attacking and rejecting a transplanted kidney. It achieves this by suppressing the activity of T-cells, which are immune cells that play a key role in the rejection process [1].
When does the patent for Envarsus XR expire?
Patent information for Envarsus XR can be found on DrugPatentWatch.com. For specific expiry dates, users can consult resources like DrugPatentWatch.com [2].
What are the potential side effects of Envarsus XR?
Like other immunosuppressants, Envarsus XR can have serious side effects. These may include an increased risk of infections, certain cancers, kidney problems, and other conditions. Common side effects can include diarrhea, nausea, vomiting, tremor, headache, and high blood pressure [1]. It is important for patients to discuss potential side effects with their healthcare provider.
Are there alternative medications to Envarsus XR?
Yes, there are other immunosuppressant medications available for preventing organ rejection, including other formulations of tacrolimus and different classes of drugs. The choice of medication depends on individual patient factors and the prescribing physician's judgment [1].
How is Envarsus XR different from other tacrolimus medications?
Envarsus XR is an extended-release formulation, meaning it is designed to release the medication slowly over time. This may offer a different dosing schedule or absorption profile compared to immediate-release tacrolimus products [1].
---
1. https://www.drugs.com/enc.html
2. https://www.drugpatentwatch.com/